Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 5/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.40 |
| ▸ | DUT | P33316 | 2/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772163 | 0.91 | DPP4 (0.42) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL770562 | 0.89 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL772459 | 0.81 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL770291 | 0.76 | GAA (0.56) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL772523 | 0.76 | PRCP (0.50) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL771118 | 0.76 | PRCP (0.50) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL802601 | 0.75 | ALDH1A1 (0.49) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL770751 | 0.74 | DPP4 (0.54) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL771117 | 0.74 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL770615 | 0.74 | DRD2 (0.49) | NPC1RAB9ASMN1; SMN2HSD11B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439202-B1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SALVAT LAB SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.